Optimeos
2 known investors
Optimeos develops a nanoparticle-based drug formulation and delivery platform (CINCs and LINCs) for complex biologics including mRNA, DNA, peptides, and proteins, targeting rare diseases, immunology, and metabolic conditions such as obesity. Its technology enables intracellular and long-acting delivery for pharmaceutical and biotech partners addressing challenges like tissue targeting and dosing profiles.
Founders & leadership
BP
Bob Prud'hommeLeadership (PhD)
RP
Rob PagelsLeadership (PhD)
CM
Chet MarkwalterLeadership (PhD)
SH
Shahram HejaziLeadership (PhD)
GH
Gregory HarrimanLeadership (MD)
ME
Mark EspositoLeadership (PhD)
Board
JS
Jason SmithLeadership (PhD)
Investors · 2
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2023 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $287.7K |
| National Science Foundation | Phase ISTTR | 2021 | $256K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $255.4K |
| National Science Foundation | Phase ISTTR | 2019 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Optimeos do?
- Optimeos develops a nanoparticle-based drug formulation and delivery platform (CINCs and LINCs) for complex biologics including mRNA, DNA, peptides, and proteins, targeting rare diseases, immunology, and metabolic conditions such as obesity. Its technology enables intracellular and long-acting delivery for pharmaceutical and biotech partners addressing challenges like tissue targeting and dosing profiles.
- Who founded Optimeos?
- Optimeos was founded by Bob Prud'homme, Rob Pagels, Chet Markwalter.
- Who are Optimeos's investors?
- Optimeos's investors include 7G BioVentures, Anzu Partners.